BIOCENTURY reported that advisory committees for peptides and RP1 are poised to test FDA credibility over composition and conflict-of-interest disclosures in compounding-related oversight. The coverage flags that seven compounding panel members have ties to peptide businesses and that the RP1 roster remains undisclosed. The story centers on how disclosure rules and committee composition can affect investor and patient confidence when regulatory decisions intersect with rapidly evolving compounding practices. It also ties into broader questions about how regulators manage industry influence when evidence is still emerging. While the article does not describe an approval or a specific enforcement action, it signals a watchpoint for governance and transparency that could affect how stakeholders interpret FDA’s regulatory posture. For biotech companies operating in peptide and related modalities, committee credibility and perceived independence can influence the pace of product development, partnering, and clinical trial design assumptions.